A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity.
Some members of the ribonuclease superfamily, such as Onconase, are cytotoxic to cancer cells. This is not the case for human pancreatic ribonuclease. This lack of cytotoxicity is probably a result of the inhibition exerted by the cytosolic ribonuclease inhibitor once the protein has reached the cytosol. Until now, all cytotoxic human pancreatic ribonuclease variants have been described as being resistant to the inhibitor. Here, we report on the characterization of a cytotoxic variant of human pancreatic ribonuclease which has an Arg triplet introduced onto one of its surface-exposed loops. Despite its sensitivity to the inhibitor, this variant, called PE5, was only 5-15 times less cytotoxic than Onconase. When it was taken up by cells, it was only observed within late compartments of the endocytic pathway, probably because the number of molecules transported to the cytosol was too small to allow their visualization. Nuclear import assays showed that the Arg triplet endows PE5 with a nuclear localization signal. In these experiments, PE5 was efficiently transported to the nucleus where it was initially localized in the nucleolus. Although the Arg introduction modified the net charge of the protein and somehow impaired recognition by the cytosolic inhibitor, control variants, which had the same number of charges or were not recognized by the inhibitor, were not toxic. We concluded that targeting a ribonuclease to the nucleus results in cytotoxicity. This effect is probably due to ribonuclease interference with rRNA processing and ribosome assembly within the nucleolus.
Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciències, Universitat de Girona, Campus de Montilivi s/n, E-17071 Girona, Spain.
Montserrat
M
Bosch
Antoni
A
Benito
Marc
M
Ribó
Teresa
T
Puig
Bruno
B
Beaumelle
Maria
M
Vilanova
D021581:Active Transport, Cell Nucleus / Q000235:genetics; D002384:Catalysis; D002467:Cell Nucleus / Q000201:enzymology / Q000235:genetics; D015195:Drug Design; D004705:Endocytosis / Q000235:genetics; D004791:Enzyme Inhibitors / Q000737:chemistry; D004795:Enzyme Stability / Q000235:genetics; D014644:Genetic Variation; D006131:Growth Inhibitors / Q000037:antagonists & inhibitors / Q000138:chemical synthesis* / Q000235:genetics / Q000633:toxicity*; D006367:HeLa Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D007424:Intracellular Fluid / Q000201:enzymology; D007527:Isoenzymes / Q000096:biosynthesis / Q000138:chemical synthesis / Q000235:genetics / Q000633:toxicity; D020014:K562 Cells; D016297:Mutagenesis, Site-Directed; D019913:Nuclear Localization Signals / Q000096:biosynthesis / Q000138:chemical synthesis* / Q000235:genetics / Q000633:toxicity*; D012259:Ribonuclease, Pancreatic / Q000037:antagonists & inhibitors / Q000138:chemical synthesis* / Q000235:genetics / Q000633:toxicity*
D004791:Enzyme Inhibitors; D006131:Growth Inhibitors; D007527:Isoenzymes; D019913:Nuclear Localization Signals; D012259:Ribonuclease, Pancreatic